Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
Parkinson’s disease may in part be driven by autoimmune processes, according to researchers who discovered that certain immune cells react to alpha-synuclein — a protein that accumulates in the ... Read more
A range of biomarkers may help physicians predict which Parkinson’s disease patients will develop cognitive decline in the early years of a diagnosis, say researchers at the University of ... Read more
Experts from ATCC — a leading nonprofit repository of biological materials — partnered with the Michael J. Fox Foundation for Parkinson’s Research for a workshop at the recent International Society ... Read more
Flexilev microtablets containing both levodopa/carbidopa, used with an automatic dose dispenser, seemed to improve self-reported symptom control in some patients with Parkinson’s disease, according to a first report of the treatment’s ... Read more
Researchers at two world-renowned institutions have presented a new theory of how Parkinson’s disease (PD) and its symptoms develop— challenging the dominant view that PD emerges as the protein alpha-synuclein spreads ... Read more
Georgetown University will conduct a clinical trial of Novartis’ cancer therapy Tasigna (nilotinib) as a treatment for Parkinson’s disease. The Phase 2 trial follows a report last year that ... Read more
Lowering the level of a certain protein can prevent PINK1 gene mutations from triggering an inherited type of Parkinson’s disease (PD), according to a study. The research may provide new insights ... Read more